DESTINY-Breast06: T-DXd significantly improves PFS in HER2-low and HER2-ultralow metastatic breast cancer

Breast Cancer

Do you want to read an article? Please log in or register.

ASCO 2024

Reference

Curigliano G, Hu X, Dent RA, et al. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). Presented at: 2024 ASCO Annual Meeting; 2–6 June 2024. Chicago, IL, USA. Oral presentation LBA1000.

Visit the healthbook ASCO 2024 newsroom here.

Reference

Related content

DESTINY-Breast12: T-DXd proved effective in patients with HER2-positive metastatic breast cancer with or without brain metastases

EMBER-3: Imlunestrant significantly improves PFS in patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations

Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis

PADMA: First-line palbociclib plus ET improves TFF and PFS versus chemotherapy in patients with high-risk HR-positive/HER2-negative metastatic breast cancer

TROPION-Breast01: PROs data reinforce Dato-DXd as a potential new therapeutic option for HR-positive, HER2-negative metastatic breast cancer

SACI-IO HR+: Adding pembrolizumab to sacituzumab govitecan shows numerical PFS improvement in HR-positive, HER2-negative breast cancer

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial

DESTINY-Breast03: Long-term data support the superiority of T-DXd over T-DM1

Updates on ADCs in treatment of advanced breast cancer